Biopharma | November 28, 2025
Exyte completes Pharmaplan integration
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Renalyx will continue operating as an independent unit within the group
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time
Subscribe To Our Newsletter & Stay Updated
